Mustang Bio (MBIO) Projected to Post Quarterly Earnings on Wednesday

Mustang Bio (NASDAQ:MBIO – Get Free Report) will likely be issuing its Q3 2026 results on Wednesday, November 18th. Analysts expect Mustang Bio to announce earnings of ($140.00) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:00 AM ET.

Mustang Bio (NASDAQ:MBIO – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($140.00) by $139.86.

Mustang Bio Stock Performance

Shares of MBIO stock opened at $0.39 on Tuesday. Mustang Bio has a 1 year low of $0.35 and a 1 year high of $1.43. The stock’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $0.66.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a research report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the company has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on Mustang Bio

Mustang Bio Company Profile

(Get Free Report)

Mustang Bio is a U.S.-based biotechnology company focused on developing cell and gene therapies for cancer and rare genetic diseases. The company has been a subsidiary of Fortress Biotech and has operated primarily as a developer of investigational treatments rather than as a commercial drug company. Its research has included CAR T-cell therapies, which modify a patient’s immune cells to target cancer. Historical programs have included MB-106, directed at the CD20 protein found on certain B-cell cancers, and MB-101, an investigational therapy targeting IL13Rα2 in glioblastoma.

Featured Stories

Earnings History for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.